Effexor for Menopause: Do Antidepressants Really Help Hot Flashes?

Effexor and menopause hot flashes: does it work, and by how much?

Yes. In randomized trials, venlafaxine, the medicine in Effexor XR, cut hot flashes more than a placebo, a dummy pill. The gain is real but moderate.

Venlafaxine is an SNRI, short for serotonin and norepinephrine reuptake inhibitor. It keeps more of two brain messengers active. Paroxetine and escitalopram are SSRIs, selective serotonin reuptake inhibitors, which act mainly on serotonin.

The first big trial, in breast cancer survivors

A 2000 trial in The Lancet tested venlafaxine in 221 women. They had a history of breast cancer, or avoided hormones for fear of it. Over four weeks, three doses were compared with placebo.

• 75 mg or 150 mg a day. Hot flash scores fell by a median of 61%. The score combines how often flashes hit and how strong they are.
• 37.5 mg a day. Scores fell by 37%.
• Placebo. Scores fell by 27%. Placebo usually helps somewhat in hot flash trials, which is why its number matters.

Dry mouth, less appetite, nausea and constipation were more common at the two higher doses than on placebo.

The head-to-head trial against estrogen

The US research network MsFLASH then put venlafaxine up against low-dose estrogen. Its 2014 trial in JAMA Internal Medicine enrolled 339 women in perimenopause or after menopause. Each had at least two bothersome hot flashes a day, and the trial lasted eight weeks.

• Venlafaxine ER 75 mg. Hot flashes fell by 47.6%, from about eight a day to about four.
• Low-dose estradiol pill, 0.5 mg. Hot flashes fell by 52.9%.
• Placebo. Hot flashes fell by 28.6%.

The gap between estradiol and venlafaxine was small, too small to rule out chance. The authors called both effective, with estradiol possibly a little better.

In plain numbers, venlafaxine removed about two more hot flashes a day than placebo did.

Why would I take an antidepressant if I'm not depressed?

Being offered one does not mean anyone thinks you're depressed. Here the target is your body's thermostat, not your mood.

Hot flashes start in the hypothalamus, the brain area that keeps your temperature steady. Researchers think serotonin and norepinephrine help it do that job, and that falling estrogen upsets the balance. The exact mechanism is still not fully known.

The dose can be different too. Brisdelle contains 7.5 mg of paroxetine. The Paxil label's starting dose for depression is 20 mg.

Brisdelle's label is blunt about it. It is not approved to treat any psychiatric condition, and its low dose has not been shown to work for one.

Venlafaxine is different. The Effexor XR label starts most adults with depression at 75 mg a day, the same dose MsFLASH tested for hot flashes.

Low mood can be part of the picture too. Our guide to perimenopause depression explains how mood shifts in this stage and how it is treated.

Paroxetine for menopause: the one FDA-approved antidepressant

Paroxetine 7.5 mg, sold as Brisdelle, won FDA approval on June 28, 2013. It treats moderate to severe vasomotor symptoms, the medical name for hot flashes and night sweats.

Its label sets a single dose, one 7.5 mg capsule at bedtime. Generic paroxetine mesylate 7.5 mg capsules were approved in 2017.

Every other antidepressant in this guide is used off-label. Off-label means prescribing an approved drug for a use the FDA has not reviewed. It is legal and common when trials back it up.

What the Brisdelle trials found

Two placebo-controlled trials, published in Menopause in 2013, enrolled nearly 1,200 women. One ran 12 weeks and the other 24 weeks. Women started at a median of about 10 hot flashes a day.

• 12-week trial. At week 12, hot flashes fell by 5.9 a day on paroxetine and by 5.0 on placebo.
• 24-week trial. At week 12, they fell by 5.6 a day on paroxetine and by 3.9 on placebo.

So the edge over placebo was one to two hot flashes a day. That is modest, but it held up in both trials.

The boxed warning, explained

A boxed warning is the strongest alert the FDA puts on a label. Brisdelle's is the warning antidepressants share: in short-term trials, they raised suicidal thoughts and behavior in children and young adults.

Brisdelle is not approved for those age groups. Its label still asks for close watch for new or worse thoughts of suicide.

The label also warns that paroxetine may make tamoxifen, a breast cancer drug, work less well. That gets its own section below.

Which antidepressant works best for hot flashes?

No single trial has compared them all, so nobody can rank them precisely. Each was tested against placebo in its own group of women, for its own length of time.

The table shows what each trial tested. It is a record of the research, not a dosing plan.

Escitalopram

In an MsFLASH trial in JAMA in 2011, 205 healthy women in menopause took escitalopram or placebo for eight weeks. Nearly half were Black women, and race did not change the result.

Hot flashes fell by half or more in 55% of women on escitalopram, compared with 36% on placebo.

Citalopram

A 2010 trial in the Journal of Clinical Oncology randomized 254 women past menopause to citalopram or placebo for six weeks. Hot flash scores fell by about half on citalopram, compared with 23% on placebo.

Doses above 10 mg added no clear extra effect on hot flashes. The National Cancer Institute's review still describes citalopram's results across studies as mixed.

Desvenlafaxine

Desvenlafaxine, sold as Pristiq, is made from venlafaxine. Its maker asked the FDA to approve it for hot flashes. In 2007 the agency asked for more heart and liver safety data, and the use was never approved.

A 2024 trial of 57 women taking tamoxifen found it beat placebo over four weeks. That is a small study.

Sertraline and fluoxetine

The National Cancer Institute's review says sertraline trials have not given convincing evidence. Fluoxetine, sold as Prozac, has been studied, but it strongly blocks the liver enzyme tamoxifen depends on.

How fast do antidepressants work for hot flashes?

Within weeks, not months, in the trials.

• Paroxetine 7.5 mg. In both Brisdelle trials, it already beat placebo at week 4.
• Venlafaxine. The 2000 Lancet trial lasted four weeks, and the effect showed by its end.
• Escitalopram. The MsFLASH trial checked at week 4 and ended at week 8.

A two-week log of your hot flashes before you start makes the change easy to judge. Count them each day, then count again at the one-month mark.

Side effects women over 40 ask about

In the Brisdelle trials, most side effects were mild or moderate. The FDA labels give the numbers.

Paroxetine 7.5 mg

The Brisdelle label's adverse reaction table, from its pooled trials, lists three effects seen more often than on placebo.

• Headache. 6.3% of women, compared with 4.8% on placebo.
• Tiredness. 4.9%, compared with 2.8% on placebo.
• Nausea or vomiting. 4.3%, compared with 2.3% on placebo.

Weight and sex drive deserve a straight answer. A pooled analysis of the Brisdelle trials found no meaningful weight gain and no drop in sexual function on paroxetine 7.5 mg, over up to 24 weeks.

Venlafaxine, Effexor XR

The Effexor XR label's figures come from depression and anxiety trials, often at higher doses than hot flash trials used.

• Nausea. 30% on Effexor XR, compared with 12% on placebo.
• Sweating, including night sweats. 11%, compared with 3% on placebo. The FAQ below explains this odd twist.
• Dry mouth, poor sleep and sleepiness. Each was more common than on placebo.
• Lower sex drive. 5%, compared with 2% on placebo.
• Blood pressure. Venlafaxine can raise it. The label asks for a check before you start and regularly after.

Warnings these drugs share

• Bleeding. These drugs raise the risk of bruising and bleeding, more so with warfarin or NSAID pain relievers such as ibuprofen.
• Low sodium, or hyponatremia. Older adults and people on diuretics, also called water pills, face higher risk.
• Serotonin syndrome. A rare but dangerous reaction, more likely when drugs that raise serotonin are combined.
• Angle-closure glaucoma. A sudden rise in eye pressure, in people with narrow eye angles that haven't been treated.
• Bone fractures. The Brisdelle label notes a link between SSRIs and fractures, without proof the drug causes them.

After breast cancer or on tamoxifen: which antidepressant is safer?

This is where antidepressants matter most. Many breast cancer survivors can't take estrogen, and hot flashes are one of tamoxifen's most common side effects.

The catch is a liver enzyme called CYP2D6. Your body uses it to turn tamoxifen into endoxifen, its stronger active form. Some antidepressants block this enzyme, which can leave less active drug in your blood.

Paroxetine blocks it strongly. The Brisdelle and Paxil labels both warn that it may make tamoxifen less effective.

The Paxil label goes further. For women taking tamoxifen for breast cancer, it tells prescribers to consider an antidepressant with little or no CYP2D6 effect.

Much of the concern traces to a 2010 study in the BMJ. It followed 2,430 women aged 66 and older in Ontario, Canada, who took tamoxifen along with one SSRI.

The more their tamoxifen time overlapped with paroxetine, the higher their risk of dying of breast cancer. No such link showed up with other antidepressants.

It was an observational study, so it shows a link, not proof. A 2025 update from Massachusetts General Hospital's Center for Women's Mental Health calls the later evidence mixed. It sorts antidepressants by how strongly they block CYP2D6.

• Strong blockers. Paroxetine, fluoxetine and bupropion.
• Moderate blockers. Citalopram, escitalopram, sertraline and duloxetine.
• Weak blockers. Venlafaxine, desvenlafaxine and fluvoxamine.

Venlafaxine is a weak blocker, and its first big hot flash trial was in breast cancer survivors. The same MGH update notes that gabapentin, a nerve medicine, doesn't affect tamoxifen at all.

The label warning is about tamoxifen. Aromatase inhibitors, such as letrozole and anastrozole, are not part of it.

Antidepressants vs HRT, Veozah and Lynkuet

Hormone therapy remains the strongest hot flash treatment. Mayo Clinic says antidepressants don't work as well for strong hot flashes, but can help women who can't use hormones.

MsFLASH is the rare trial that tested both side by side, and the gap there was small. It used a low estrogen dose, for eight weeks.

Hormone safety labels changed this year. In February 2026, the FDA removed heart disease, breast cancer and probable dementia from the boxed warning on hormone therapy labels.

Two newer non-hormonal pills were built for hot flashes. They block neurokinin receptors, part of the brain's temperature control.

• Veozah, or fezolinetant. In its first main trial, women started with about 10 moderate to severe hot flashes a day. At week 12 they had about 6.4 fewer, compared with 3.9 fewer on placebo.
• Veozah's warnings. A boxed warning for liver injury, with blood tests before and during treatment. It is not for women with cirrhosis, severe kidney disease or kidney failure, or who take drugs that block the CYP1A2 enzyme.
• Lynkuet, or elinzanetant. FDA-approved on October 24, 2025. In its OASIS 1 trial, women started near 13 hot flashes a day and had about 8.7 fewer at week 12, compared with 5.4 fewer on placebo. OASIS 2 showed a similar gap.
• Lynkuet's warnings. No boxed warning. It is not for use in pregnancy, and the label warns about daytime sleepiness, liver enzyme rises and seizures.

The real trade-off is cost and track record. These antidepressants are old generics with decades of use, while the new pills cost hundreds of dollars a month in cash.

For the full picture, read Veozah vs HRT, our Veozah review, or the overview of all menopause treatment options.

Coming off an antidepressant: why you taper

Stopping suddenly can bring on discontinuation symptoms. Paroxetine and venlafaxine are known for them.

The Effexor XR label recommends "a gradual reduction in the dose, rather than abrupt cessation." It adds that some people need several months to come off.

Its list of discontinuation symptoms includes dizziness, nausea, headache, anxiety, nightmares, sweating and brief shock-like sensations.

The Paxil label also says to lower the dose gradually whenever possible. In the Brisdelle trials, these symptoms were more common than on placebo, mostly after an abrupt stop, and usually faded on their own.

Hot flashes can come back, too. In the escitalopram trial, three weeks after stopping, hot flashes rose more in women who had taken the drug than in the placebo group.

The taper schedule comes from your prescriber, matched to the drug and dose you take.

Is an antidepressant the right medicine for menopause hot flashes?

Often a good fit

• You can't take hormones. For example, after breast cancer or a blood clot.
• You'd rather not take hormones. That is a valid reason on its own.
• Your hot flashes are moderate to severe. That is the group Brisdelle is approved for.
• You want a cheap generic. Most of these drugs cost little with a free coupon.

Reasons to pause or choose another option

• You take tamoxifen. Paroxetine's labels advise considering a different antidepressant.
• You take an MAOI. These older antidepressants can't be combined with Brisdelle or Effexor XR. The labels also require a waiting gap of up to 14 days when switching.
• You have high blood pressure. Venlafaxine can raise it, so it needs watching.
• You have bipolar disorder. The labels ask prescribers to screen for it first, because antidepressants can trigger mania.
• You could be pregnant. Brisdelle's label rules it out in pregnancy, and pregnancy is still possible in perimenopause.
• You have untreated narrow-angle glaucoma. The labels say to avoid these drugs.

Already on an SSRI and still flushing?

Brisdelle is the same drug family. Its label warns that combining drugs that raise serotonin increases the risk of serotonin syndrome.

So the useful question is a switch, or a different kind of treatment, rather than a second serotonin drug on top. Our guide to perimenopause hot flashes covers the other options.

How to get a prescription, and what it costs

Any prescriber can write these, including a primary care doctor, a gynecologist or a telehealth service. Most are inexpensive generics.

Cash prices with a free SingleCare coupon, checked on October 21, 2026:

• Generic paroxetine mesylate 7.5 mg, Brisdelle's generic. About $70 to $110 for 30 capsules, depending on the pharmacy.
• Generic venlafaxine ER 150 mg. About $5 to $25 for 30 capsules.
• Generic escitalopram 10 mg. About $5 to $25 for 30 tablets.
• Alloy, online. Prescribes low-dose paroxetine after a one-time $49 consult. Its product page names a regular 10 mg tablet, not the 7.5 mg capsule approved for hot flashes.

Coupon prices shift by pharmacy and week. To compare online prescribers, see our menopause telehealth comparison.

When to call your clinician right away

This list follows the FDA Medication Guide for Brisdelle. Call your prescriber or go to the nearest emergency room if you notice any of these.

• Thoughts about suicide or dying, or new or worse depression, anxiety or panic attacks.
• Acting on dangerous impulses, or feeling agitated, restless, angry, aggressive or violent.
• Unusual changes in mood or behavior, such as far more energy or talking than is normal for you.
• Signs of serotonin syndrome. Agitation, hallucinations or confusion, a racing heartbeat, sweating or fever, muscle twitching or stiffness, tremor, dizziness, nausea, vomiting or diarrhea.
• High fever, stiff muscles, confusion or fainting after mixing with an MAOI.

The same guide lists other serious side effects to report promptly.

• Unusual bleeding or bruising, especially if you also take warfarin or an NSAID.
• Eye pain, vision changes, or swelling or redness around the eye.
• Signs of low sodium. Headache, weakness, feeling unsteady, confusion or fainting.
• Signs of mania. Racing thoughts, reckless behavior, or barely needing sleep.
• A seizure.